Background: The combination of paclitaxel (P) and carboplatin (C) is an effective treatment for advanced NSCLC. Gemcitabine (G) is an active new drug. We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination. A phase II study was subsequently conducted to evaluate the activity and toxicity of PCG.
Introduction
About two thirds of patients with non-small-cell lung cancer (NSCLC) have locally advanced or metastatic disease [1] . The optimal management of these patients is controversial, but there is general agreement [2] that cisplatin-based chemotherapy, when compared with best supportive care alone, improves survival [3] , quality of life [4] and symptoms [5, 6] . However, the survival benefit is small, with an increased median survival of six weeks and the one-year survival rate improved by only 10% in metastatic disease (from 15% to 25%) [3] . Furthermore, the efficacy of classical cisplatin-based programs is such that no specific regimen can be regarded as standard therapy [7] . In particular, three-drug combinations were not clearly superior to dual drug regimens, except for one study [8] . These modest results have made the development of new agents and combinations imperative.
In the past few years, several new agents have been shown to be active in advanced NSCLC, with approximately a 20% response rate for single drugs and a favorable toxicity profile [9] . In particular, single-agent paclitaxel using different schedules has produced response rates exceeding 20% and one-year survival in the range of 40% [10, 11] . Subsequently, paclitaxel was safely combined with established drugs for NSCLC, like cisplatin [12] [13] [14] and carboplatin [15] [16] [17] [18] . The combination of carboplatin plus paclitaxel used at various doses and schedules [19] has proved active, tolerable, and easy to administer. Based on these considerations, this regimen has been included in several phase III trials both in the US and in Europe [20] . The modest toxicity of this two-drug regimen has made logical the investigation of three-drug schedules with the addition of another active compound [21, 22] . The established single agent activity of gemcitabine, together with a modest toxicity and different mechanism of action [23] , made this agent attractive to develop a triplet combination.
In this paper we report the results of a phase I study planned to define optimal doses of the triplet combination of paclitaxel, carboplatin and gemcitabine (PCG). The regimen was then evaluated in a phase II study to assess its activity and toxicity.
Patients and methods
In October 1996, we started a phase I study to define the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of the PCG combination. After the completion of the phase I study, the activity and the toxicity of the regimen were evaluated in a phase II study.
Eligibility criteria were identical for the two portions of the study. Patients were required to have histologically or cytologically proven stage IIIB, or unresectable IIIA with bulky N 2 disease, or stage IV NSCLC, with measurable disease. Patients with recurrent metastatic disease following surgery were eligible for the study; prior radiotherapy or chemotherapy was not allowed. Patients with brain metastases could be enrolled only if they had no neurological symptom and had another measurable site of disease.
Patients were eligible if they were between 18 and 70 years of age and had a performance status (PS) of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale. Normal hepatic, renal and hematological parameters (absolute neutrophil count > 2000/ul, platelet count >100,000/ul, creatinine <1.5 mg/dl, bilirubin <l.5 mg/dl) were required. Patients with a history of acute myocardial infarction within the last six months or with arrhythmias or chronic heart failure requiring permanent medication were excluded from the study. Patients treated for any other type of cancer during the previous five years and patients with serious co-existing medical illnesses were also excluded. A negative pregnancy test was needed for women of childbearing potential. The study was carried out with the approval of local ethics committees. All patients gave written informed consent prior to beginning treatment.
Treatment plan
The phase I part of this trial was coordinated by the Medical Oncology Department of Padua. Eligible patients were enrolled sequentially at the planned dose level from four centers (Medical Oncology Department of Padua, Aviano and Modena, and Radiochemotherapy Department of San Raffaele Hospital, Milan). After completion of the phase I portion of the study, additional patients for the phase II study were enrolled from six different centers of the GSTPV (Gruppo Studio Tumori Polmonari Veneto), including the four above cited. Carboplatin dose was calculated using the Calvert formula [24] , with an area under the concentration/time curve of 6 mg/ml/min, and was given as a 30-minute intravenous infusion on day 1. Paclitaxel and gemcitabine were alternately escalated in order to find the MTD. Paclitaxel starting dose was 175 mg/m 2 by three-hour infusion on day 1, with increments of 25 mg/m 2 ; gemcitabine was given on days 1 and 8 by 30-minute infusion with escalation of dose from 800 mg/m 2 and increments of 200 mg/m 2 . The combination was recycled in the outpatient setting every three weeks. The premedication schedule consisted of dexamethasone 16 mg i.v. one hour prior to paclitaxel infusion, intramuscular orphenadrine 40 mg and i.v. ranitidine 50 mg 30 minutes before beginning of treatment. Paclitaxel was administered first, followed by carboplatin and then by gemcitabine. Patients received i.v. prophylactic antiemetic therapy with a 5-HT 3 antagonist before treatment, which was continued orally for 48 hours. Use of granulocyte colony-stimulating factor (G-CSF) was not allowed in the phase I part of the study. In the phase II study, G-CSF was administered only when complications occurred, according to the recommendations of the American Society of Clinical Oncology [25] . A short duration of administration, sufficient to achieve clinically adequate neutrophil recovery, was adopted.
After two courses of treatment, all patients were assessed for response. Responders and patients with stable disease continued treatment with response evaluation every two cycles, and were submitted to a maximum of six cycles. Patients with stage III were re-evaluated for surgery after chemotherapy in the case of response; unresectable cases were submitted to radiation therapy with curative intent, at doses of 60-65 Gy.
DLT and dose escalation
Hematological DLT was defined as: WHO grade 4 neutropenia with neutrophil count <500/ul lasting for >7 days or neutrophil count < 100/|il lasting for > 3 days, or any episode of febrile neutropenia; or WHO grade 4 thrombocytopenia requiring platelet transfusion.
Non-hematological DLT was defined as any WHO grade > 3 toxicity excluding alopecia, vomiting, severe muscle-skeletal pain or mucositis for less than seven days.
Doses were not escalated in individual patients. Three to six patients were treated at each dose level. If no DLT occurred in the first three patients, the next dose level was explored. If a DLT occurred in one out of three cases, three additional patients were treated at that dose level. If DLT occurred in two or more out of six patients, further dose escalation was stopped, and that dose level was designated as the MTD. The recommended phase II dose was defined as the dose level below the MTD.
Evaluations
Baseline evaluations included: patient medical history, physical examination, complete blood cell count (CBC) with differential and platelet count, liver and kidney function tests, ECG, computed tomography (CT) scans of the chest, abdomen and brain, and whole bone scan.
During treatment, CBCs with differential and platelet count were performed weekly, while biochemical tests and physical examination were repeated every three weeks.
All patients who completed two cycles of chemotherapy were evaluated for response, according to WHO criteria [26] . A complete response (CR) was defined as the disappearance of all lesions for at least four weeks; a partial response (PR) required a 5t 50% decrease in the tumor size (the sum of the products of the largest perpendicular diameters of all measurable lesions); stable disease (SD) was defined as less than a 50% decrease or less than a 25% increase in tumor size. Progressive disease (PD) was defined as an increase of at least 25% in tumor size or the appearance of new lesions. Patients with a rapid objective progression after one cycle were considered PD. All patients who received at least one course of treatment were included in the analysis of treatment-related toxicities which were recorded according to WHO criteria [26] . All patients registered on the study were evaluated in the survival analysis.
Statistical methods
Confidence limits (95% CI) of response rate were estimated [27] . Time to progression (TTP) was defined as the period from the first day of treatment to the date of first evidence of disease progression; survival (Sv) was calculated from the first day of therapy until death or last follow-up. Actuarial survival curves were generated using the method of Kaplan and Meier [28] .
Results
A total of 45 patients entered the study. Their characteristics are listed in Table 1 . Three patients (7%) had asymptomatic brain metastases, detected during baseline staging by brain CT scan. These patients entered the study protocol and were treated concomitantly for central nervous system disease with whole brain radiation, with a careful evaluation of brain toxicity; for these patients response was evaluated on other sites of measurable disease outside the brain.
A total of 187 treatment cycles were delivered, with a median of 4 per patient (range 1-6 cycles). 25 (56) 20 (44) 28 (62) 17 (38) 21 (47) 18 (40) 6 (13) Abbreviation: ECOG -Eastern Cooperative Oncology Group. Abbreviations AUC -area under curve according to Calvert formula [24] ; N-H -non-hematological; DLT -dose limiting toxicity
Phase I study
Fourteen patients, divided in three dose levels, were evaluated in the phase I study (Table 2) . A total of 60 cycles was delivered. Myelosuppression was the main toxicity, with grade 4 neutropenia in 9 of 14 patients and grade 4 thrombocytopenia in 2 cases. DLTs were reported at the third level: one case of febrile neutropenia and one case of grade 3 diarrhea. Based on phase I results, doses for the phase II study were as follows: carboplatin AUC 6 on day 1, paclitaxel 175 mg/m 2 as a three-hour infusion on day 1 and gemcitabine 1000 mg/m 2 on days 1 and 8.
Phase II study
Thirty-one patients were treated in the phase II study. All except one were assessable for response. This patient was lost to follow-up after the second cycle of chemotherapy and not evaluated. Two patients were not assessable for hematological toxicity, because weekly CBCs were not performed. The treatment was well tolerated by most patients. No patient refused to continue chemotherapy for reasons directly related to the treatment toxicity. Therapy was discontinued only if disease progression was observed or at the completion of the planned number of cycles. 
(%) 4 (%)
Leucopenia Thrombocytopenia Anemia 15 (13) 8 (7) 12 (10) 6 (5) 9(75) 0(0) 6 (21) 4(14) 5 (17) 5(17) Gemcitabine was omitted on day 8 in 13% of cycles, and reduced to 50% in 15 cycles. A reduction to 75% of the planned dose of the three drugs was necessary in 14 cycles. Myelosuppression was the main toxicity (Table 3) , with grade 3-4 leukopenia witnessed in 10 patients (35% of the whole phase II study group). Three cases of septic fever requiring hospitalization were observed. G-CSF was administered to six patients only (19% of the phase II group). Anemia and thrombocytopenia were common as well. Twenty-four percent of patients experienced grade 3 anemia and required packed red blood cell transfusions. Grade 3 or 4 thrombocytopenia occurred in 10 patients. Non-hematological toxicity is summarized in Table 4 . Nausea and vomiting were mild and easily controlled with antiemetics. The arthralgia/myalgia syndrome was common, but it was severe in 9% of cases only. Peripheral neuropathy was equally frequent, and generally developed after the third or fourth course of chemotherapy. Severe neurotoxicity was observed in 6% of patients. No hypersensitivity reaction occurred; all patients experienced complete alopecia and fatigue. No unexpected brain toxicity was observed in the three patients receiving brain radiation.
Patients treated in the phase I portion of the study were included in response and survival analysis. There were 2 CR and 25 PR, for an overall response rate of 60% (95% confidence interval (95% CI): 44%-74%). Response rate was 68% (95% CI: 48%-84%) in stage III patients and 47% (95% CI: 23%-72%) in stage IV.
The respective figures for squamous and non-squamous tumors were 72% (95% CI: 46%-90%) and 52% (95% CI: 32%-71%).
Six patients with stage III disease underwent surgery after the completion of chemotherapy; in one case, preoperative RT was also performed: this patient had no evidence of disease at thirty-one months of followup. Among the other 5 cases (2 IIIA, 3 IIIB), 4 were free of disease at a median follow-up of 24 months; the last 1 developed a second neoplasm (a biopsy-proven sarcoma of the base of the skull) at 15 months: a surgical resection was attempted, but the patient died shortly after the intervention. Due to the short time of latency, this tumor was judged not treatment induced. At surgery, a pathological complete remission was observed in two out of the five patient treated preoperatively with chemotherapy. All these five patients had achieved a clinical PR after chemotherapy. Patients with unresectable stage III NSCLC after chemotherapy were submitted to radiation therapy with doses of 60-65, with no excessive lung toxicity. One patient treated with chemoradiation therapy and no surgery was free of disease at thirty-one months.
Median TTP in responders was 12 months. Median survival for the entire population was 17.2 months; oneyear survival was 60% and two-year survival was 29%. Median survival and one-year actuarial survival were 20.5 months and 74.5% for patients with stage III and 11.5 months and 47% for stage IV disease.
Discussion
The present paper reports the results of a phase I-II trial describing the use of PCG combination in chemonaive patients with locally advanced or metastatic NSCLC.
In the phase I part of the trial, this regimen was shown to be feasible and tolerable. Febrile neutropenia and, unexpectedly, grade 3 diarrhea were reported as DLTs. Based on phase I results, doses for the phase II study were as follows: carboplatin AUC 6 on day 1, paclitaxel 175 mg/m 2 as a three-hour infusion on day 1 and gemcitabine 1000 mg/m 2 on days 1 and 8. These doses are slightly different from those reported by two other phase I trials [29, 30] with the same combination, in which a higher dose of paclitaxel and a lower carboplatin AUC were obtained.
In the phase II portion of our study, the PCG combination confirmed a good tolerability profile. All patients were treated in an outpatient setting. Myelosuppression was the main toxicity observed in the 29 valuable phase II patients, with 34% of patients developing grade 3-4 thrombocytopenia at least once during the treatment; however, no patient had severe bleeding complications. The rate of grade 3-4 leukopenia was similar. A septic fever was observed in four cycles (3 patients), but it was easily managed with antibiotic therapy. The use of G-CSF support was allowed in this part of the trial and it likely reduced in some cases the incidence of prolonged neutropenia. G-CSF was administered in selected patients only, when an high risk of infection was predictable, and for a short duration, stopping G-CSF treatment when a clinically adequate neutrophil recovery was achieved. Actually, G-CSF was used in 19% of patients only. Grade 3 anemia was observed in 24% of patients, who received packed red blood cell transfusions. The incidence of severe anemia was less than that observed in the study of the Sarah Cannon Cancer Center study [29] ; this is possibly due to the lower dose of paclitaxel in our schedule. On the contrary, the rate of severe leukopenia and thrombocytopenia were very similar. With the PCG regimen, myelosuppression was increased in comparison with the two-drug combination of paclitaxel and carboplatin [22, 29] ; however, the rate of hospitalization for febrile neutropenia and the incidence of treatment-related deaths were not increased in the present and in the others series.
Since neutropenia can be easily managed by the administration of G-CSF, peripheral neuropathy has become one of the main dose-limiting toxicities in paclitaxel-based chemotherapy [31] . Its severity increases with increasing single and cumulative drug doses and is accentuated by short infusions and in regimens also containing a platinum analogue [32] . Severe cumulative peripheral neuropathy occurred in 6% of the patients in our series, while grade 2 was observed in 17%. These results are comparable to the percentages reported by the groups from the Sarah Cannon Cancer Center and from the University of Colorado Cancer Center, and which were previously experienced in trials employing the twodrug combination of paclitaxel with carboplatin [22, 29] .
The PCG combination proved effective, with an overall response rate of 60% (95% CI: 44%-74%) evaluated on the whole study population (14 patients of the phase I and 31 patients of the phase II study). An additional 29% of patients had minor responses or stable disease. Among the 30 valuable patients of the phase II study, the response rate was very similar (17 responders, 57%). Median duration of response was 12 months. Median survival of the 45 patients was 17.2 months, one-year survival rate 60%. These data obviously reflect the high percentage of stage III patients (mostly IIIB) in the study population. However, data for stage IV patients confirmed the promising results of a recently published phase II study evaluating the same combination in advanced NSCLC [29] .
The response rate and survival of our series seem slightly superior to those obtained with the more widely used two-drug paclitaxel-carboplatin combination [9, 22, 29] , but this is not based on statistical analyses. However, these data are confirmed by the preliminary results of a recently published randomized study [33] . Particularly encouraging is the activity in patients with stage III disease, which is comparable to that of the more active cisplatin-based combinations [34] , even though no superiority has been demonstrated in comparison to two-drug paclitaxel-carboplatin combination in this group of patients [35] . Of special interest are the data in patients submitted to surgery after PCG, with promising results in terms of complete pathological response.
The issue of the role of non-cisplatin regimens (in particular the combination of paclitaxel and carboplatin) in first-line treatment of advanced NSCLC is still unresolved, as no superiority has been observed of this regimen in any randomized trial with a proven cisplatinbased combination chemotherapy [36] [37] [38] [39] . Moreover, the data available from literature concerning the use of carboplatin rather than cisplatin are controversial. The results of three randomized trials that have compared carboplatin to cisplatin combinations in NSCLC showed no significant difference in terms of response rates and survival, while the toxicity was generally less in the carboplatin arm [38, 40, 41] . Future trials should also assess the role of carboplatin in PCG in comparison to similar cisplatin-based three-drug regimens [42, 43] .
In view of our results, we started a phase III study comparing paclitaxel plus carboplatin to this three-drug combination. In addition, we are planning to introduce the PCG regimen in the treatment of stage II-III patients in the setting of a multimodality treatment.
